NCT06415344Phase 3Terminated

Long-term Extension of GTX-102 in Angelman Syndrome

Study sponsor: Ultragenyx Pharmaceutical Inc · RARE

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-10-30Actual
Enrollment · participants66Actual
Source updated2026-11-03Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 255 participants (planned). After: 66 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Feb 2029. After: 30 Oct 2026.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

· 1 field changed

Recruitment status changed

Before: Enrolling by invitation. After: Active not recruiting.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Frequency, Severity, and Relationship to Investigational Drug of Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs). After: Measure: Incidence of Treatment Emergent Adverse Events (TEAEs).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview